The weight loss market is the gift that keeps on giving—at least for Novo Nordisk—as Wegovy continues to demonstrate its prowess with label expansion.
Also discussed: biosimilar approvals for Fresenius Kabi, and Sandoz.
More news at the forefront of Alzheimer's treatment: Eli Lilly's donanemab decision date got pushed and now the FDA wants to discuss the drug’s safety and efficacy at an upcoming adcomm.
And finally, politics: President Biden's State of the Union address ruffles feathers as he strikes out at Big Pharma and drug prices, and how the industry is reacting to the election.